Published in Diab Vasc Dis Res on March 15, 2015
Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes. Cardiovasc Diabetol (2015) 0.92
HbA1c below 7 % as the goal of glucose control fails to maximize the cardiovascular benefits: a meta-analysis. Cardiovasc Diabetol (2015) 0.86
Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events. Cardiovasc Diabetol (2015) 0.85
Interpretation of cardiovascular outcome trials in type 2 diabetes needs a multiaxial approach. World J Diabetes (2015) 0.85
Dipeptidyl Peptidase 4 Inhibitors and the Risk of Cardiovascular Disease in Patients with Type 2 Diabetes: A Tale of Three Studies. Diabetes Metab J (2015) 0.83
Cardiovascular outcome trials for anti-diabetes medication: A holy grail of drug development? Indian Heart J (2016) 0.82
Cardiovascular risk with DPP-4 inhibitors: latest evidence and clinical implications. Ther Adv Drug Saf (2015) 0.79
Current perspectives on cardiovascular outcome trials in diabetes. Cardiovasc Diabetol (2016) 0.79
Gliptins and Cardiovascular Outcomes: A Comparative and Critical Analysis after TECOS. J Diabetes Res (2015) 0.78
Cardiovascular Outcome Studies in Diabetes: How Do We Make Sense of These New Data? Diabetes Ther (2016) 0.77
Vildagliptin reduces plasma stromal cell-derived factor-1α in patients with type 2 diabetes compared with glimepiride. J Diabetes Investig (2016) 0.75
Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials. Adv Ther (2016) 0.75
Recent cardiovascular outcome trials of antidiabetic drugs: A comparative analysis. Indian J Endocrinol Metab (2017) 0.75
No increased risk of cardiovascular events in older adults initiating dipeptidyl peptidase-4 inhibitors vs therapeutic alternatives. Diabetes Obes Metab (2017) 0.75
Management of patients with type 2 diabetes and mild/moderate renal impairment: profile of linagliptin. Ther Clin Risk Manag (2015) 0.75
Cardiovascular effects of anti-diabetes drugs. Expert Opin Drug Saf (2016) 0.75
Pro- and Antiarrhythmic Actions of Sulfonylureas: Mechanistic and Clinical Evidence. Trends Endocrinol Metab (2017) 0.75
Effects of glucose-lowering agents on ischemic stroke. World J Diabetes (2017) 0.75
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care (2012) 21.62
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med (2013) 11.34
Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med (2013) 8.74
Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation (2014) 5.32
Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med (2011) 4.76
A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes (1970) 4.57
Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ (2013) 2.74
The potential for renoprotection with incretin-based drugs. Kidney Int (2014) 2.48
Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors. Atherosclerosis (2013) 1.83
Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes Care (2013) 1.79
Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes. Expert Opin Investig Drugs (2010) 1.46
The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos (2010) 1.40
Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial. Diab Vasc Dis Res (2013) 1.36
Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. Vascul Pharmacol (2011) 1.34
The effects of dipeptidyl peptidase-4 inhibition on microvascular diabetes complications. Diabetes Care (2014) 1.00
Sulphonylurea monotherapy for patients with type 2 diabetes mellitus. Cochrane Database Syst Rev (2013) 0.93
Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence. Diabetes Obes Metab (2011) 0.92
The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury. Basic Res Cardiol (2011) 0.91
Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials. Diabetes Metab Res Rev (2014) 0.89
A note on stratifying versus complete random assignment in clinical trials. Control Clin Trials (1982) 0.87
C-peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2-year double-blind, randomized, controlled study. Diabetes Care (2014) 0.84
DPP-4 inhibition and neuroprotection: do mechanisms matter? Diabetes (2013) 0.80
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J (2016) 1.41
The relative associations of β-cell function and insulin sensitivity with glycemic status and incident glycemic progression in migrant Asian Indians in the United States: the MASALA study. J Diabetes Complications (2013) 0.88
Efficacy and safety of linagliptin in Asian patients with type 2 diabetes mellitus inadequately controlled by metformin: A multinational 24-week, randomized clinical trial. J Diabetes (2015) 0.83
Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA-T2D™ trial. Diab Vasc Dis Res (2015) 0.81
Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes. Am J Kidney Dis (2015) 0.79
Ethnic differences in hepatic and systemic insulin sensitivity and their associated determinants in obese black and white South African women. Diabetologia (2015) 0.77
Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial. Eur Heart J (2017) 0.76
Linagliptin for elderly patients with type 2 diabetes - Authors' reply. Lancet (2014) 0.75
Longitudinal Plasma Kallikrein Levels and Their Association with the Risk of Cardiovascular Disease Outcomes in Type 1 Diabetes in DCCT/EDIC. Diabetes (2020) 0.75
Double-heterozygous autosomal dominant hypercholesterolemia: Clinical characterization of an underreported disease. J Clin Lipidol (2016) 0.75
Letter to the editor regarding: "Pharmacokinetics of teneligliptin in subjects with renal impairment." Halabi et al., Clinical Pharmacology in Drug Development 2013;2:246-254. Clin Pharmacol Drug Dev (2014) 0.75
Erratum to: Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetes. Cardiovasc Diabetol (2015) 0.75
THE EFFECT OF STATINS ON CARDIOVASCULAR OUTCOMES BY SMOKING STATUS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. Pharmacol Res (2017) 0.75